Kim Y D, Foegh M L, Wallace R B, Ng L, Ahmed S W, Katz N M, Siegelman R, Franco K, Douglas F, Ku E
Department of Anesthesia, Georgetown University School of Medicine, Washington, DC 20007.
Circulation. 1988 Sep;78(3 Pt 2):I44-50.
Pulmonary hypertension with an elevated pulmonary vascular resistance was observed during the immediate recovery period in patients who underwent mitral valve surgery. In eight such patients, intravenous infusion of CGS-13080, imidazo(1,5-a)pyridine-5-hexanoic acid (a thromboxane synthetase inhibitor), at a dose range of 0.08-0.1 mg/kg/hr, effectively reduced pulmonary hypertension (from a mean pulmonary arterial pressure of 36 +/- 2 to 31 +/- 2 torr) and pulmonary vascular resistance (from 339 +/- 38 to 238 +/- 37 dynes.sec.cm-5) within 30 minutes and remained reduced for the entire infusion period (48 hours in five patients and 18 hours in three patients). Mean arterial pressure or systemic vascular resistance were not significantly affected by the drug infusion. Serum thromboxane B2 levels (a stable metabolic product of thromboxane A2) were significantly reduced after administration of the compound, with the maximum effect of greater than 90% reduction. All patients tolerated the drug infusion without significant side effects.
在接受二尖瓣手术的患者术后即刻恢复期观察到伴有肺血管阻力升高的肺动脉高压。在8例此类患者中，静脉输注CGS - 13080，即咪唑并(1,5 - a)吡啶 - 5 - 己酸（一种血栓素合成酶抑制剂），剂量范围为0.08 - 0.1 mg/kg/小时，在30分钟内有效降低了肺动脉高压（平均肺动脉压从36±2降至31±2托）和肺血管阻力（从339±38降至238±37达因·秒·厘米⁻⁵），并且在整个输注期间（5例患者为48小时，3例患者为18小时）持续降低。药物输注对平均动脉压或体循环血管阻力无显著影响。给予该化合物后，血清血栓素B2水平（血栓素A2的稳定代谢产物）显著降低，最大降幅超过90%。所有患者均耐受药物输注，无明显副作用。
